thalidomide has been researched along with Carcinogenesis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 7.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 3.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Xu, L | 1 |
| Mayakonda, A | 1 |
| Huang, ML | 1 |
| Kanojia, D | 1 |
| Tan, TZ | 1 |
| Dakle, P | 1 |
| Lin, RY | 1 |
| Ke, XY | 1 |
| Said, JW | 1 |
| Chen, J | 1 |
| Gery, S | 1 |
| Ding, LW | 1 |
| Jiang, YY | 1 |
| Pang, A | 1 |
| Puhaindran, ME | 1 |
| Goh, BC | 1 |
| Koeffler, HP | 1 |
| Guo, L | 1 |
| Wan, Z | 1 |
| Xu, B | 1 |
| Ren, L | 1 |
| Liu, H | 1 |
| Song, N | 1 |
| Liu, L | 1 |
| Pascutti, F | 1 |
| Cunha, LL | 1 |
| Rizzatti, EG | 1 |
| Colleoni, GW | 1 |
3 other studies available for thalidomide and Carcinogenesis
| Article | Year |
|---|---|
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.
Topics: Animals; Azepines; Base Sequence; Carcinogenesis; Cell Line, Tumor; Enhancer Elements, Genetic; Geno | 2019 |
Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Hemangioendothelioma; Humans; Mice; Ribonu | 2019 |
Understanding myeloma cancer stem cells.
Topics: Animals; Carcinogenesis; Cell Proliferation; Humans; Immunosuppressive Agents; Mice; Multiple Myelom | 2013 |